NCT03829930 is a Phase 1 clinical trial of Entinostat in Prostate Adenocarcinoma, sponsored by George Washington University.

Who is sponsoring NCT03829930?

NCT03829930 is sponsored by George Washington University.

What drugs are being tested in NCT03829930?

Interventions in NCT03829930: Entinostat, Enzalutamide.

What condition does NCT03829930 study?

NCT03829930 studies Prostate Adenocarcinoma.

Is NCT03829930 still recruiting?

NCT03829930 is currently terminated. Last updated 2 August 2021.

Last reviewed 2021-08-02 · How we verify

NCT03829930

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer

Terminated Phase 1 Last updated 2 August 2021

What this trial tests

Phase 1 trial testing Entinostat in Prostate Adenocarcinoma in 6 participants. Terminated before completion.

Timeline

1 May 2019

Primary endpoint
1 September 2020

1 September 2020

Quick facts

Lead sponsor	George Washington University
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	1 May 2019
Primary completion	1 September 2020
Estimated completion	1 September 2020
Sites	1 location across United States

Drugs / interventions tested

Entinostat — full drug profile →
Enzalutamide (enzalutamide) — full drug profile →

Conditions studied

Prostate Adenocarcinoma — all drugs for Prostate Adenocarcinoma →

Sponsor

George Washington University

Who can join

18 and older, male only, with Prostate Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the safety and tolerability of Entinostat in combination with Enzalutamide in metastatic castrate resistant prostate cancer

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.
Dai E, Zhu Z, Wahed S, Qu Z, et al · · 2021 · cited 224× · PMID 34930302 · DOI 10.1186/s12943-021-01464-x
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.
He Y, Xu W, Xiao YT, Huang H, et al · · 2022 · cited 192× · PMID 35750683 · DOI 10.1038/s41392-022-01042-7
Epigenetics-targeted drugs: current paradigms and future challenges.
Dai W, Qiao X, Fang Y, Guo R, et al · · 2024 · cited 131× · PMID 39592582 · DOI 10.1038/s41392-024-02039-0
Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing.
Majchrzak-Celińska A, Warych A, Szoszkiewicz M. · · 2021 · cited 85× · PMID 33572577 · DOI 10.3390/genes12020208
Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer.
Kumaraswamy A, Welker Leng KR, Westbrook TC, Yates JA, et al · · 2021 · cited 51× · PMID 33785255 · DOI 10.1016/j.eururo.2021.03.005
Epigenetic modifications in diabetes.
Kowluru RA, Mohammad G. · · 2022 · cited 46× · PMID 34715117 · DOI 10.1016/j.metabol.2021.154920
Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer.
Pramanik SD, Kumar Halder A, Mukherjee U, Kumar D, et al · · 2022 · cited 24× · PMID 36034650 · DOI 10.3389/fchem.2022.948217
Autoimmune disease: a view of epigenetics and therapeutic targeting.
Mu S, Wang W, Liu Q, Ke N, et al · · 2024 · cited 21× · PMID 39606248 · DOI 10.3389/fimmu.2024.1482728

Verify or expand the search:

Other trials of Entinostat

Trials testing the same drug.

NCT07441486 — A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment · Phase 2 · not yet recruiting
NCT07261592 — Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer · Phase 1, PHASE2 · not yet recruiting
NCT05898828 — Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Th · Phase 1, PHASE2 · withdrawn
NCT05053971 — Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors · Phase 1, PHASE2 · recruiting
NCT04708470 — A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, · Phase 1, PHASE2 · active not recruiting

Other recruiting trials for Prostate Adenocarcinoma

Currently open trials in the same condition.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
NCT06957691 — Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Pro · Phase 2 · recruiting
NCT07025369 — Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With H · Phase 2 · recruiting
NCT06967961 — Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers · NA · recruiting

Other George Washington University trials

Trials by the same sponsor.

NCT07279129 — Decision Support Tool to Integrate PrEP Into Emergency Departments · Phase 1 · not yet recruiting
NCT07524309 — Self-Help Plus Pilot Study, Colombia: Train2Care · NA · not yet recruiting
NCT07249008 — NSS Grocery Store Brazil · NA · recruiting
NCT07000513 — HIV Self-Testing and Long-Acting Injectables for HIV Treatment and Prevention Among Commercial Minibus Drivers (I-TEST L · Phase 4 · not yet recruiting
NCT07079306 — ChatGPT-Supported Text Messaging Program for Smoking Cessation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03829930 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by George Washington University
Last refreshed: 2 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03829930.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing